Provided by Tiger Trade Technology Pte. Ltd.

Prelude Therapeutics Inc

4.59
-0.0800-1.71%
Post-market: 4.52-0.0700-1.53%19:57 EDT
Volume:520.54K
Turnover:2.42M
Market Cap:365.56M
PE:-6.39
High:4.75
Open:4.72
Low:4.56
Close:4.67
52wk High:6.83
52wk Low:0.9807
Shares:79.64M
Float Shares:4.56M
Volume Ratio:1.23
T/O Rate:11.42%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7183
EPS(LYR):-1.2929
ROE:-57.73%
ROA:-27.15%
PB:2.73
PE(LYR):-3.55

Loading ...

Prelude Therapeutics Shareholders Back Leadership and Governance

TIPRANKS
·
Jun 11

Prelude Therapeutics shareholders elect three directors at annual meeting

Reuters
·
Jun 11

Prelude Therapeutics initiated with Early-Stage Biotech at Goldman Sachs

TIPRANKS
·
May 15

Prelude Therapeutics (PRLD) Losses Narrow In Q1 2026 Challenging Bearish Narratives

Simply Wall St.
·
May 14

Prelude Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 12

Prelude Therapeutics reports Q1 EPS (13c), consensus (27c)

TIPRANKS
·
May 12

Prelude Therapeutics Q1 EPS $(0.13) Beats $(0.25) Estimate, Sales $4.580M

Benzinga Earnings
·
May 12

Prelude Therapeutics Q1 net loss narrows as expenses fall

Reuters
·
May 12

BRIEF-Prelude Therapeutics Q1 EPS USD -0.13

Reuters
·
May 12

Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 12

Prelude Therapeutics Q1 Operating Expenses USD 18.757 Million

THOMSON REUTERS
·
May 12

Prelude Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
May 08

Prelude Therapeutics Initiated at Buy by D. Boral Capital

Dow Jones
·
May 04

Prelude Therapeutics Advances First‑in‑Human PRT12396 Trial in High‑Risk Blood Cancers

TIPRANKS
·
May 03

Prelude Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Reuters
·
May 01

Prelude Therapeutics initial beneficial ownership statement names RA Capital Management

Reuters
·
Apr 29

Prelude Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Apr 27

Prelude Therapeutics Incorporated : H.c. Wainwright Raises Target Price to $8 From $5

THOMSON REUTERS
·
Apr 27

Massive Insider Buying Spree Signals Bold Confidence in Prelude Therapeutics

TIPRANKS
·
Apr 24

OrbiMed Advisors acquires $12.5 million Prelude Therapeutics common shares

Reuters
·
Apr 24